




Instance: composition-en-4c464411361072df4cc109cbbcdd523e
InstanceOf: CompositionUvEpi
Title: "Composition for sunosi Package Leaflet"
Description:  "Composition for sunosi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp74d62ddf25094051bb178fa09599f013)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sunosi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sunosi is and what it is used for </li>
<li>What you need to know before you take Sunosi </li>
<li>How to take Sunosi </li>
<li>Possible side effects </li>
<li>How to store Sunosi </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sunosi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sunosi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sunosi contains the active substance solriamfetol. Solriamfetol increases the amount of the natural 
substances dopamine and norepinephrine in your brain. Sunosi helps you to stay awake and to feel 
less sleepy. </p>
<p>It is used 
* in adults with narcolepsy, a condition that causes you to suddenly and unexpectedly feel very 
sleepy at any time. Some patients with narcolepsy also have symptoms of cataplexy (when 
muscles become weak in response to emotions such as anger, fear, laughter or surprise, 
sometimes leading to collapse). </p>
<ul>
<li>to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with 
obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA 
therapy, such as continuous positive airway pressure (CPAP).  </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sunosi if you: 
* are allergic to solriamfetol or any of the other ingredients of this medicine (listed in section 6) 
* had a heart attack in the past 1 year 
* have serious heart problems, such as chest pain of recent onset, or chest pain that is lasting 
longer or is more severe than usual, high blood pressure not properly controlled with 
medicines, serious irregular heart beat or other serious heart problems 
* are taking a type of medicine called a  monoamine oxidase inhibitor  (MAOI) for 
depression or Parkinson s disease, or have taken an MAOI in the last 14 days. 
Warnings and precautions 
Talk to your doctor or pharmacist before taking Sunosi if you have or have had: </p>
<ul>
<li>mental health problems, including psychosis (altered sense of what is real) and extreme changes 
in mood (bipolar disorder) </li>
<li>heart problems, heart attack or stroke </li>
<li>high blood pressure </li>
<li>alcoholism or any drug abuse or dependence </li>
<li>an eye condition called angle closure glaucoma. </li>
</ul>
<p>Tell your doctor or pharmacist if any of the above applies to you before starting treatment. This is 
because Sunosi may make some of these problems worse. Your doctor will want to monitor how the 
medicine affects you. </p>
<p>Sunosi does not replace your OSA primary treatment such as CPAP. You should continue to use such 
treatment as well as Sunosi. </p>
<p>Children and adolescents 
Sunosi is not recommended in children or adolescents under 18 years of age. The safety and efficacy 
are not yet known in this age group. </p>
<p>Other medicines and Sunosi 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Do not take Sunosi if: 
* you are taking a medicine called a  monoamine oxidase inhibitor  (MAOI) for depression or 
Parkinson s disease, or have taken an MAOI in the last 14 days because taking an MAOI with 
Sunosi may increase your blood pressure. </p>
<p>Check with your doctor or pharmacist if you are taking medicines that can increase your blood 
pressure or heart rate, or if you are taking dopaminergic agents (e.g. pramipexole, levodopa, 
methylphenidate) which are used to treat Parkinson s disease, depression, restless leg syndrome and 
ADHD.  </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Sunosi should not be used during pregnancy or in women of childbearing potential not using effective 
contraception. </p>
<p>You should not use Sunosi during breast-feeding. You and your doctor must decide whether to avoid 
breast-feeding or to stop or avoid Sunosi therapy, taking into account the benefit of breast-feeding 
for you and your child and the benefit of therapy for you. </p>
<p>Driving and using machines 
You may feel dizzy or your ability to concentrate may be impaired; take special care when driving or 
using machines.  </p>
<p>Talk to your doctor or pharmacist if you are not sure how your underlying condition or this medicine 
affects you with activities that require attention, such as driving and handling machinery: 
* at the beginning of treatment 
* if your dose is changed </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>How much Sunosi to take 
Your doctor will advise you on the dose of Sunosi to take. 
* For narcolepsy, treatment is normally started with a dose of 75 mg once per day, in the morning 
when you wake up. Some patients may need a 150-mg starting dose. Your doctor will advise 
you if this applies to you. Your doctor may prescribe you a lower dose of 37.5 mg. You can get 
this dose by taking half of one 75 mg tablet. The tablet should be broken using the score line. </p>
<ul>
<li>
<p>For OSA, treatment is normally started with a dose of 37.5 mg once per day, in the morning 
when you wake up. You can get this dose by taking half of one 75 mg tablet. The tablet should 
be broken using the score line. </p>
</li>
<li>
<p>After at least 3 days  treatment, your doctor may increase your daily dose to the most appropriate 
dose. </p>
</li>
</ul>
<p>The recommended maximum dose of Sunosi is 150 mg daily. </p>
<p>Elderly (aged more than 65 years) 
Take the usual daily dose unless you have kidney problems (see below  Patients with kidney 
problems ). </p>
<p>Patients with kidney problems 
If you have kidney problems your doctor may need to adjust the dose. </p>
<p>Taking Sunosi 
* Sunosi is for oral use 
* Take Sunosi by mouth in the morning when you wake up. 
* You can take Sunosi with food or between meals. </p>
<p>How long to take Sunosi 
You should continue to take Sunosi for as long as you are told to by your doctor. </p>
<p>If you take more Sunosi than you should 
The following symptoms were observed when patients received Sunosi 900mg (6 times the 
maximum daily dose): uncontrollable movements (tardive dyskinesia) and feeling restless and unable 
to keep still (akathisia). These symptoms resolved when Sunosi was stopped. </p>
<p>Contact your doctor or nearest emergency department immediately for advice. Take this leaflet and 
any remaining tablets with you. </p>
<p>If you forget to take Sunosi 
If you forget to take your medicine at the usual time, you can still take it if it is more than 9 hours 
before bedtime. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Sunosi 
Discuss with your doctor before you stop taking Sunosi. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Headache </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Anxiety, difficulty sleeping, irritability, dizziness, feeling jittery, excessive sweating 
* Fast or irregular heart beats, also called palpitations, chest discomfort 
* High blood pressure<br />
* Feeling sick, diarrhoea, stomach pain, constipation, vomiting 
* Cough, clenching or grinding your teeth, dry mouth 
* Loss of appetite </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Feeling agitated, restlessness, inability to concentrate, shaking (tremors) 
* Increase in heart rate much higher than normal 
* Shortness of breath 
* Chest pain 
* Thirst 
* Weight loss </p>
<p>Skin rash, hives and itching have also been reported. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the bottle / blister after 
 EXP . The expiry date refers to the last day of that month.  </p>
<p>Blisters: This medicine does not require any special storage conditions. </p>
<p>Bottles: Once opened, use within 4 months. Keep the container tightly closed in order to protect from 
moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sunosi contains 
The active substance is solriamfetol. </p>
<p>Sunosi 75 mg film-coated tablets 
Each tablet contains solriamfetol hydrochloride, equivalent to 75 mg of solriamfetol. </p>
<p>Sunosi 150 mg film-coated tablets 
Each tablet contains solriamfetol hydrochloride, equivalent to 150 mg of solriamfetol. </p>
<p>The other ingredients are: 
Tablet cores: Hydroxypropyl cellulose, magnesium stearate </p>
<p>Film coating: polyvinyl alcohol, macrogol, talc, titanium dioxide (E171), iron oxide yellow (E172). </p>
<p>What Sunosi looks like and contents of the pack 
Film-coated tablet </p>
<p>Sunosi 75 mg film-coated tablets 
Yellow to dark yellow/orange oblong tablet with  75  debossed on one side and a score line on the 
opposite side. The tablet can be divided into equal doses. </p>
<p>Sunosi 150 mg film-coated tablets<br />
Yellow oblong tablet with  150  debossed on one side. </p>
<p>Sunosi is available in blister packs of 7 x 1 film-coated tablets in PVC/PCTFE/Aluminium perforated 
unit dose blisters, 28 and 56 film-coated tablets and in bottles of 30 and 100 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder 
Atnahs Pharma Netherlands B. V. 
Copenhagen Towers 
 restads Boulevard 108, 5.tv 
DK-2300 K benhavn S 
Denmark </p>
<p>Manufacturer 
Cilatus Manufacturing Services Limited<br />
Pembroke House 
28-32 Pembroke Street Upper 
Dublin 2 
Co. Dublin 
 D02 EKIreland </p>
<p>This leaflet was last revised in MM/YYYY. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website:<br />
http://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-da-4c464411361072df4cc109cbbcdd523e
InstanceOf: CompositionUvEpi
Title: "Composition for sunosi Package Leaflet"
Description:  "Composition for sunosi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp74d62ddf25094051bb178fa09599f013)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sunosi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Sunosi </li>
<li>Sådan skal du tage Sunosi </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sunosi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sunosi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sunosi indeholder det aktive stof solriamfetol. Solriamfetol øger mængden af de naturlige stoffer, 
dopamin og noradrenalin, i hjernen. Sunosi hjælper dig med at holde dig vågen og føle dig mindre 
søvnig. </p>
<p>Det anvendes til </p>
<ul>
<li>
<p>voksne med narkolepsi, en sygdom, der gør, at du pludseligt og uventet og på vilkårlige 
tidspunkter føler dig meget søvnig. Nogle patienter med narkolepsi har også symptomer på 
katapleksi (hvor musklerne bliver svage som en reaktion på følelser som vrede, angst, latter eller 
overraskelser, hvilket til tider kan føre til kollaps). </p>
</li>
<li>
<p>at forbedre vågenhed og reducere overdreven søvnighed i løbet af dagen (Excessive Daytime 
Sleepiness, EDS) hos voksne patienter med obstruktiv søvnapnø (OSA), hvis EDS ikke er 
tilfredsstillende behandlet med primær OSA-behandling, såsom kontinuerligt positivt 
luftvejstryk (Continuous Positive Airway Pressure, CPAP). </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sunosi, hvis du: </p>
<ul>
<li>
<p>er allergisk over for solriamfetol eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet 
i punkt 6) </p>
</li>
<li>
<p>har haft et hjerteanfald i løbet af det seneste år </p>
</li>
<li>
<p>har alvorlige hjerteproblemer, såsom brystsmerter, der er startet for nyligt, eller brystsmerter, 
som varer længere eller er sværere end normalt, højt blodtryk, som ikke er velkontrolleret 
med medicin, alvorligt uregelmæssigt hjerteslag eller andre alvorlige hjerteproblemer </p>
</li>
<li>
<p>tager en type lægemiddel, der kaldes en 'monoaminooxidasehæmmer’ (MAO-hæmmer) mod 
depression eller Parkinsons sygdom, eller du har taget en MAO-hæmmer i løbet af de sidste 
14 dage. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Sunosi, hvis du har eller tidligere har lidt af: </p>
<ul>
<li>
<p>psykiske problemer, herunder psykose (ændret realitetssans) og ekstreme humørsvingninger 
(bipolær sygdom) </p>
</li>
<li>
<p>hjerteproblemer, hjerteanfald eller slagtilfælde </p>
</li>
<li>
<p>forhøjet blodtryk </p>
</li>
<li>
<p>alkoholisme eller stofmisbrug eller -afhængighed </p>
</li>
<li>
<p>en øjensygdom, der kaldes snævervinklet grøn stær. </p>
</li>
</ul>
<p>Kontakt lægen eller apotekspersonalet, før du starter behandlingen, hvis noget af ovenstående gælder 
for dig. Årsagen hertil er, at Sunosi kan forværre nogle af disse problemer. Din læge vil ønske at 
overvåge, hvordan medicinen påvirker dig. </p>
<p>Sunosi erstatter ikke din primære OSA-behandling, såsom CPAP. Du skal fortsætte med at bruge en 
sådan behandling sammen med Sunosi. </p>
<p>Børn og unge 
Sunosi bør ikke anvendes til børn og unge under 18 år. Sikkerhed og virkning er endnu ikke kendt for 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Sunosi 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. </p>
<p>Tag ikke Sunosi, hvis: </p>
<ul>
<li>du tager et lægemiddel, der kaldes en ‘monoaminooxidasehæmmer’ (MAO-hæmmer) mod 
depression eller Parkinsons sygdom, eller du har taget en MAO-hæmmer i løbet af de sidste 
14 dage, da det kan forhøje blodtrykket, hvis du tager en MAO-hæmmer sammen med Sunosi. </li>
</ul>
<p>Rådfør dig med lægen eller apotekspersonalet, hvis du tager lægemidler, der kan forhøje blodtrykket 
eller øge pulsen, eller hvis du tager dopaminerge stoffer (f.eks. pramipexol, levodopa, 
methylphenidat), som bruges til at behandle Parkinsons sygdom, depression, rastløse ben (restless leg-
syndrom) og ADHD. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Sunosi bør ikke anvendes under graviditeten eller til kvinder i den fødedygtige alder, som ikke 
anvender sikker prævention. </p>
<p>Du bør ikke bruge Sunosi under amning. Du skal sammen med lægen beslutte, om amning skal 
undgås, eller behandling med Sunosi skal stoppes eller undgås, idet der tages højde for fordelene ved 
amning for dig og barnet i forhold til de terapeutiske fordele for dig. </p>
<p>Trafik- og arbejdssikkerhed 
Du kan føle dig svimmel, eller din koncentrationsevne kan være nedsat. Vær ekstra forsigtig, når du 
fører motorkøretøj og betjener maskiner. </p>
<p>Kontakt lægen eller apotekspersonalet, hvis du ikke er sikker på, hvordan din underliggende sygdom 
eller dette lægemiddel påvirker dig, når du udfører aktiviteter, som kræver din opmærksomhed, såsom 
at føre motorkøretøj og betjene maskiner: </p>
<ul>
<li>
<p>når behandlingen påbegyndes </p>
</li>
<li>
<p>hvis din dosis ændres. </p>
</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Så meget Sunosi skal du tage </p>
<p>Lægen vil rådgive dig om, hvilken dosis af Sunosi du skal tage. </p>
<ul>
<li>
<p>Ved narkolepsi startes behandlingen normalt med en dosis på 75 mg én gang dagligt om 
morgenen, når du vågner. Nogle patienter kan have behov for en startdosis på 150 mg. Lægen 
vil informere dig, om dette gælder for dig. Lægen kan ordinere en lavere dosis på 37,5 mg. Du 
kan få denne dosis ved at tage en halv 75 mg-tablet. Tabletten skal knækkes ved delekærven. </p>
</li>
<li>
<p>Ved OSA startes behandlingen normalt med en dosis på 37,5 mg én gang dagligt om morgenen, 
når du vågner. Du kan få denne dosis ved at tage en halv 75 mg-tablet. Tabletten skal knækkes 
ved delekærven. </p>
</li>
<li>
<p>Efter mindst 3 dages behandling kan lægen øge din daglige dosis til den mest passende dosis. </p>
</li>
</ul>
<p>Den anbefalede maksimale dosis af Sunosi er 150 mg dagligt. </p>
<p>Ældre (i alderen over 65 år) 
Tag den sædvanlige daglige dosis, medmindre du har nyreproblemer (se nedenfor "Patienter med 
nyreproblemer"). </p>
<p>Patienter med nyreproblemer 
Hvis du har nyreproblemer, kan det være nødvendigt, at lægen justerer din dosis. </p>
<p>Sådan tager du Sunosi </p>
<ul>
<li>
<p>Sunosi er til oral anvendelse. </p>
</li>
<li>
<p>Sunosi tages via munden om morgenen, når du vågner. </p>
</li>
<li>
<p>Du kan tage Sunosi sammen med mad eller mellem måltider. </p>
</li>
</ul>
<p>Så længe skal du tage Sunosi 
Du bør fortsætte med at tage Sunosi så længe, lægen fortæller dig det. </p>
<p>Hvis du har taget for meget Sunosi 
De følgende symptomer blev observeret, efter en patient fik Sunosi 900 mg (6 gange den maksimale 
daglige dosis): ukontrollerbare bevægelser (tardiv dyskinesi) og følelse af rastløshed og manglende 
evne til at holde sig i ro (akatisi). Disse symptomer gik væk, efter behandlingen med Sunosi blev 
stoppet.  </p>
<p>Kontakt øjeblikkeligt lægen eller den nærmeste akutmodtagelse for rådgivning. Tag denne 
indlægsseddel og alle resterende tabletter med dig. </p>
<p>Hvis du har glemt at tage Sunosi 
Hvis du har glemt at tage dit lægemiddel på det sædvanlige tidspunkt, kan du stadig tage det, hvis der 
er mere end 9 timer til din sengetid. Du må ikke tage en dobbeltdosis som erstatning for den glemte 
dosis. </p>
<p>Hvis du holder op med at tage Sunosi 
Drøft det med lægen, før du holder op med at tage Sunosi. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>Hovedpine. </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>Angst, søvnbesvær, irritabilitet, svimmelhed, nervøsitet, kraftig svedtendens </p>
</li>
<li>
<p>Hurtige eller uregelmæssige hjerteslag, også kaldet hjertebanken, brystgener </p>
</li>
<li>
<p>Højt blodtryk </p>
</li>
<li>
<p>Kvalme, diarré, mavesmerter, forstoppelse, opkastning </p>
</li>
<li>
<p>Hoste, tandpres eller tænderskæren, mundtørhed </p>
</li>
<li>
<p>Appetitløshed. </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>Ophidselse, rastløshed, koncentrationsbesvær, rysten (tremor) </p>
</li>
<li>
<p>Meget hurtigere puls end normalt </p>
</li>
<li>
<p>Stakåndethed </p>
</li>
<li>
<p>Brystsmerter </p>
</li>
<li>
<p>Tørst </p>
</li>
<li>
<p>Vægttab. </p>
</li>
</ul>
<p>Der er også rapporteret om hududslæt, nældefeber og kløe. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sunosi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sunosi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og beholderen/blisteren efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned.  </p>
<p>Blister: Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Beholder: Efter anbrud skal lægemidlet anvendes i løbet af 4 måneder. Hold beholderen tæt tillukket 
for at beskytte mod fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sunosi indeholder: 
Aktivt stof: solriamfetol. </p>
<p>Sunosi 75 mg filmovertrukne tabletter 
Hver tablet indeholder solriamfetolhydrochlorid svarende til 75 mg solriamfetol. </p>
<p>Sunosi 150 mg filmovertrukne tabletter 
Hver tablet indeholder solriamfetolhydrochlorid svarende til 150 mg solriamfetol. </p>
<p>Øvrige indholdsstoffer: 
Tabletkerne: Hydroxypropylcellulose, magnesiumstearat </p>
<p>Filmovertræk: polyvinylalkohol, macrogol, talcum, titandioxid (E171), jernoxid, gul (E172). </p>
<p>Udseende og pakningsstørrelser 
Filmovertrukket tablet </p>
<p>Sunosi 75 mg filmovertrukne tabletter 
Gul til mørkegul/orange, aflang tablet med "75" præget på den ene side og med en delekærv på den 
modsatte side. Tabletten kan deles i to lige store doser. </p>
<p>Sunosi 150 mg filmovertrukne tabletter 
Gul, aflang tablet med "150" præget på den ene side. </p>
<p>Sunosi fås i blisterpakninger med 7 x 1 filmovertrukne tabletter i perforeret enhedsdosisblister af 
PVC/PCTFE/aluminium, 28 og 56 filmovertrukne tabletter og i beholdere med 30 og 
100 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelse 
Atnahs Pharma Netherlands B. V. 
Copenhagen Towers 
Ørestads Boulevard 108, 5.tv 
DK-2300 København S 
Danmark </p>
<p>Fabrikant 
Cilatus Manufacturing Services Limited<br />
Pembroke House 
28-32 Pembroke Street Upper 
Dublin 2 
Co. Dublin 
D02 EKIrland </p>
<p>Denne indlægsseddel blev senest ændret MM/YYYY. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-4c464411361072df4cc109cbbcdd523e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sunosi Package Leaflet for language en"
Description: "ePI document Bundle for sunosi Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4c464411361072df4cc109cbbcdd523e"
* entry[0].resource = composition-en-4c464411361072df4cc109cbbcdd523e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4c464411361072df4cc109cbbcdd523e"
* entry[=].resource = mp4c464411361072df4cc109cbbcdd523e
                            
                    
Instance: bundlepackageleaflet-da-4c464411361072df4cc109cbbcdd523e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sunosi Package Leaflet for language da"
Description: "ePI document Bundle for sunosi Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-4c464411361072df4cc109cbbcdd523e"
* entry[0].resource = composition-da-4c464411361072df4cc109cbbcdd523e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4c464411361072df4cc109cbbcdd523e"
* entry[=].resource = mp4c464411361072df4cc109cbbcdd523e
                            
                    



Instance: mp4c464411361072df4cc109cbbcdd523e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sunosi 75 mg film-coated tablets"
Description: "Sunosi 75 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1408/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sunosi 75 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 4c464411361072df4cc109cbbcdd523eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sunosi"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sunosi"

* subject = Reference(mp74d62ddf25094051bb178fa09599f013)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sunosi "sunosi"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-4c464411361072df4cc109cbbcdd523e) // sunosi en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-4c464411361072df4cc109cbbcdd523e) // sunosi da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-4c464411361072df4cc109cbbcdd523e
InstanceOf: List

* insert 4c464411361072df4cc109cbbcdd523eListRuleset
    